Anixa Biosciences (ANIX) announced that it has dosed its first patient in the third cohort in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor-T cell therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
Questions or Comments about the article? Write to editor@tipranks.com